|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real‐life practice显示文摘 | Hua Zhang Calvin Q. Pan Qiumei Pang Ruihua Tian Miaoe Yan Xin Liu | 2014 | Hepatology2014，，： | 1 |
| 2 | CD4(+)CD25(+) treg induction by an HSP60-derived peptide SJMHE1 from schistosoma japonicum is TLR2 dependent显示文摘Chronic schistosome infection results in the suppression of host immune responses, allowing long-term schistosome survival and restricting pathology.Current theories suggest that Treg play an important role in this regulation.However, the mechanism of Treg induction during schistosome infection is still unknown.The aim of this study was to determine the mechanism behind the induction of CD4(+)CD25(+) T cells by Schistosoma japonicum HSP60(SjHSP60)-derived peptide SJMHE1 as well as to elucidate the cellular and molecular basis for the induction of CD4(+)CD25(+) T cells during S.japonicum infection.Mice immunized with SJMHE1 or spleen and LN cells from naive mice pretreated.with SJMHE1 in vitro all displayed an increase in CD4(+)CD25(+) T-cell populations.Release of IL-10 and TGF-beta by SJMHE1 stimulation may contribute to suppression.Adoptively transferred SJMHE1induced CD4(+)CD25(+) T cells inhibited delayed-type hypersensitivity in BALB / c mice.Additionally, SJMHE1-treated APC were tolerogenic and induced CD4(+) cells to differentiate into suppressive CD4(+)CD25(+) Treg.Furthermore, our data support a role for TLR2 in SJMHE1-mediated CD4(+)CD25(+) Treg induction.These findings provide the basis for a more complete understanding of the S.japonicum-host interactions that contribute to host homeostatic mechanisms, preventing an excessive immune response. | Wang, Xuefeng Zhou, Sha Chi, Ying Wen, Xiaoyun Hoellwarth, Jason He, Lei Liu, Feng Wu, Calvin Dhesi, Shawn Zhao, Jiaqing Hu, Wei Su, Chuan | 2010 | 南京医科大学学报(自然科学版)2010，30，1： | 1 |
| 3 | Building stock market resilience through digital transformation:Using Google trends to analyze the impact of COVID-19 pandemic显示文摘As the 2019 novel coronavirus disease(COVID-19)pandemic rages globally,its impact has been felt in the stock markets around the world.Amidst the gloomy economic outlook,certain sectors seem to have survived better than others.This paper aims to investigate the sectors that have performed better even as market sentiment is affected by the pandemic.The daily closing stock prices of a total usable sample of 1,567 firms from 37 sectors are first an a lyzed using a combination of hierarchical clustering and shape-based distance(SBD)measures.Market sentiment is modeled from Google trends on the COVID-19 pandemic.This is then analyzed against the time series of daily closing stock prices using augmented vector autoregression(VAR).The empirical results indicate that market sentiment towards the pandemic has significant effects on the stock prices of the sectors.Particularly,the stock price performance across sectors is differentiated by the level of the digital transformation of sectors,with those that are most digitally transformed,showing resili ence towards negative market sentime nt on the pandemic.This study contributes to the existing literature by incorporating search trends to an a lyze market sentiment,and by showing that digital transformation moderated the stock market resilience of firms against concern over the COVID-19 outbreak. | Ding Ding Chong Guan Calvin MLChan Wenting Liu | 2020 | Frontiers of Business Research in China2020，14，3： | 1 |
| 4 | Eosinophilic Meningitis Caused by Angiostrongylus cantonensis:Report of 17 Cases显示文摘 | Tsai Hung-Chin Liu Yung-Ching Calvin M Kunin | 2001 | The American Journal of Medicine2001，111，2： | 1 |
| 5 | Increasing Hospital Admission Rates for Urological Complications After Transrectal Ultrasound Guided Prostate Biopsy显示文摘 | Robert K. Nam Refik Saskin Yuna Lee Ying Liu Calvin Law Laurence H. Klotz D. Andrew Loblaw John Trachtenberg Aleksandra Stanimirovic Andrew E. Simor Arun Seth David R. Urbach Steven A. Narod | 2010 | The Journal of Urology2010，，3： | 1 |
| 6 | What do oncologists need to know about biosimilar products?显示文摘Many biologic products have improved the outcomes of cancer patients,but the costs can substantially burden healthcare systems.Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments.Approval of a biosimilar product relies on the demonstration of 'comparability' or 'no clinically meaningful differences' as compared to its reference biologic product.Biosimilar products for erythropoietin,granulocyte colonystimulating factor,trastuzumab,and rituximab are already available,and the regulatory processes in various countries are constantly evolving.It is important that oncologists be familiar with the potential issues surrounding the clinical use of biosimilar products.In this review article,we provide background information about biosimilar products and their regulatory approval processes,followed by a discussion of individual biosimilar drugs. | Linda K.S.Leung Kevin Mok Calvin Liu Stephen L.Chan | 2016 | Chinese Journal of Cancer2016，35，11： | 0 |
| 7 | Space-confined microwave synthesis of ternary-layered BiOCl crystals with high-performance ultraviolet photodetection显示文摘In recent years,two-dimensional(2D)ternary materials have attracted wide attention due to their novel properties which can be achieved by regulating their chemical composition with a very great degree of freedom and adjustable space.However,as for the precise synthesis of 2D ternary materials,great challenges still lie ahead that hinder their further development.In this work,we demonstrated a simple and reliable approach to synthesize 2D ternary-layered BiOCl crystals through a microwave-assisted space-confined process in a short time(<3 minutes).Their ultraviolet(UV)detection performance was analyzed systematically.The photodetectors based on the as-obtained BiOCl platelets demonstrate high sensitivity to 266-nm laser illumination.The responsivity is calculated to be8 A/W and the response time is up to be18 ps.On the other hand,the device is quite stable after being exposed in the ambient air within 3 weeks and the response is almost unchanged during the measurement.The facile and fast synthesis of single crystalline BiOCl platelets and its high sensitivity to UV light irradiation indicate the potential optoelectronic applications of 2D BiOCl photodetectors. | Lixing Kang Xuechao Yu Xiaoxu Zhao Qingling Ouyang Jun Di Manzhang Xu Dan Tian Weiliang Gan Calvin CIAng Shoucong Ning Qundong Fu Jiadong Zhou R.G.Kutty Ya Deng Pin Song Qingsheng Zeng Stephen J.Pennycook Jun Shen Ken-T.Yong Zheng Liu | 2020 | InfoMat2020，2，3： | 0 |
| 8 | Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis:A Systematic Review and Meta-analysis显示文摘Background and Aims:Decompensated cirrhotic patients with hepatitis C(HCV)are often under-represented in clinical trials.We aimed to evaluate pooled data on the efficacy and safety of sofosbuvir(SOF)-based regimens in these patients.Methods:We conducted a systemic review and meta-analysis by searching multiple databases for studies published from October 2010 to October 2020.Outcomes of interest were sustained virologic response(SVR)and safety of SOFbased regimens in decompensated HCV patients.Two reviewers independently performed the study selection and data extraction.Results:We included 33 studies that enrolled 5,302 HCV patients.The pooled SVR rate in decompensated patients with SOF-based regimens was 85.1%(95%CI:82.8–87.3).Patients on SOF/velpatasvir±ribavirin achieved a significantly higher SVR(91.0%,95%CI:87.7–93.9)than that of SOF/ledipasvir±ribavirin[(86.3%,95%CI:84.6–87.8);p=0.004],or on SOF/daclatasvir±ribavirin(82.4%,95%CI:78.2–86.2%;p<0.001).Adding ribavirin to SOFbased regimens(pooled SVR 84.9%,95%CI:81.7–87.9)did not significantly increase the SVR[83.8%(95%CI:76.8–89.8%;p=0.76)]in decompensated patients,which was also true in subgroup analyses for each regimen within the same treatment duration.However,adding ribavirin significantly increased the frequency of adverse events from 52.9%(95%CI:28.0–77.1)to 89.2%(95%CI:68.1–99.9)and frequency of severe events.The pooled incidence of hepatocellular carcinoma and case-fatality of decompensated patients were 3.1%(95%CI:1.5–5.0)and 4.6%(95%CI:3.1–6.3),respectively.The overall heterogeneity was high.There was no publication bias.Conclusions:The analysis found that 12 weeks of SOF/velpatasvir without ribavirin is the preferred therapy,with a significantly higher SVR compared with other SOF-based regimens in decompensated HCV patients. | Wenyan Zhang Jing Zhang Shan Tang Yali Liu Xiaofei Du Lixia Qiu Menglu Liu Haibin Yu Calvin Q.Pan | 2023 | Journal of Clinical and Translational Hepatology2023，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员